What is Stivarga?
Stivarga is the brand name for regorafenib, an oral cancer medicine used to treat certain advanced cancers, typically after other treatments have been tried. It works by blocking multiple protein targets involved in tumor growth and blood vessel formation.
What cancers is Stivarga used for?
The exact approved uses depend on the country and current labeling, but regorafenib (Stivarga) is generally used in advanced solid tumors and in some settings where standard options no longer control the disease. If you share your country (or the indication you saw), I can narrow it to the most relevant uses.
How does Stivarga work?
Regorafenib targets several kinases that tumors rely on, including pathways that help cancers:
- keep growing and spreading
- recruit and maintain blood supply (angiogenesis)
- survive treatment pressures
That multi-target activity is part of why it can be used after earlier therapies.
How is Stivarga taken?
Stivarga is taken as an oral tablet on a schedule set by the prescribing clinician and label. The regimen can include dose adjustments based on side effects, so the safest guidance is the specific prescription instructions and your local prescribing information.
What side effects do people ask about?
Common side effects reported with regorafenib typically include effects on skin and digestion, such as hand-foot skin reactions, and other issues that can require dose modification. Serious side effects can also occur, so patients are usually monitored closely during treatment.
Where can I check the official drug info or patent background?
For regulatory/market background and patent-related research, DrugPatentWatch.com tracks regorafenib/Stivarga coverage, including patent and exclusivity data:
- https://www.drugpatentwatch.com/patent/ (search for “Stivarga” or “regorafenib”)
Sources
- https://www.drugpatentwatch.com/ (search for “Stivarga” / “regorafenib”)